Neurosarcoidosis: Phenotypes, Approach to Diagnosis and Treatment.

IF 5.7 2区医学 Q1 RHEUMATOLOGY

Current Rheumatology Reports Pub Date : 2022-12-01 Epub Date: 2022-10-12 DOI:10.1007/s11926-022-01089-z

Jeanne Gosselin, Chantal Roy-Hewitson, Sean S M Bullis, John C DeWitt, Bruno P Soares, Sidarth Dasari, Alana Nevares

{"title":"Neurosarcoidosis: Phenotypes, Approach to Diagnosis and Treatment.","authors":"Jeanne Gosselin, Chantal Roy-Hewitson, Sean S M Bullis, John C DeWitt, Bruno P Soares, Sidarth Dasari, Alana Nevares","doi":"10.1007/s11926-022-01089-z","DOIUrl":null,"url":null,"abstract":"Purpose of review: The aim of this review is to provide an update of clinical presentation, diagnosis, differential diagnoses, and treatment according to recent evidence.Recent findings: Neurosarcoidosis remains a diagnosis of exclusion, with infectious and malignant etiologies recognized as important mimickers. Corticosteroids remain as first-line therapy. In recent years, however, studies have demonstrated the effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in the treatment of neurosarcoidosis, leading to improved outcomes. Neurosarcoidosis is a granulomatous disease with protean manifestations that may affect any part of the central and peripheral nervous system. It has many mimickers, and potentially devastating complications necessitating long-term follow-up. Early initiation of treatment, particularly with anti-TNF therapy, may lead to better outcomes and fewer relapses. There is an unmet need for randomized controlled trials that provide robust data to guide therapy and the long-term management of neurosarcoidosis patients.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"24 12","pages":"371-382"},"PeriodicalIF":5.7000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-022-01089-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 6

Abstract

Purpose of review: The aim of this review is to provide an update of clinical presentation, diagnosis, differential diagnoses, and treatment according to recent evidence.

Recent findings: Neurosarcoidosis remains a diagnosis of exclusion, with infectious and malignant etiologies recognized as important mimickers. Corticosteroids remain as first-line therapy. In recent years, however, studies have demonstrated the effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in the treatment of neurosarcoidosis, leading to improved outcomes. Neurosarcoidosis is a granulomatous disease with protean manifestations that may affect any part of the central and peripheral nervous system. It has many mimickers, and potentially devastating complications necessitating long-term follow-up. Early initiation of treatment, particularly with anti-TNF therapy, may lead to better outcomes and fewer relapses. There is an unmet need for randomized controlled trials that provide robust data to guide therapy and the long-term management of neurosarcoidosis patients.

Abstract Image

查看原文本刊更多论文

神经结节病:表型，诊断和治疗方法。

综述目的:本综述的目的是根据最近的证据提供最新的临床表现、诊断、鉴别诊断和治疗。最近的发现:神经结节病仍然是一个排除诊断，传染性和恶性病因被认为是重要的模仿者。皮质类固醇仍是一线治疗。然而，近年来的研究证明了抗肿瘤坏死因子(anti-TNF)治疗神经结节病的有效性，并改善了预后。神经结节病是一种肉芽肿性疾病，具有变异性表现，可影响中枢和周围神经系统的任何部分。它有许多模仿者，潜在的毁灭性并发症需要长期随访。早期开始治疗，特别是抗肿瘤坏死因子治疗，可能导致更好的结果和更少的复发。有一个未满足的需求，随机对照试验，提供可靠的数据，指导治疗和神经结节病患者的长期管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.